Source comparison
Comparison: Tesamorelin + Ipamorelin vs Monotherapy Protocols
Tesamorelin Monotherapy GHRH-R only 180–220% 90–120 minutes None. Endogenous somatostatin rises to counter Once nightly Effective but ceiling-limited by feedback inhibition Ipamorelin Monotherapy GHS-R1a only 140–180% 120–150 minutes Moderate. Blocks somatosta
This comparison does not assign a generated winner or score.
- Tesamorelin Monotherapy
- GHRH-R only
- 180–220%
- 90–120 minutes
- None. Endogenous somatostatin rises to counter
- Once nightly
- Effective but ceiling-limited by feedback inhibition
- Ipamorelin Monotherapy
- GHS-R1a only
- 140–180%
- 120–150 minutes
- Moderate. Blocks somatostatin release
- Flatter curve, lacks transcriptional GH synthesis boost
- Tesamorelin + Ipamorelin Blend
- GHRH-R + GHS-R1a
- 320–380%
- 150–180 minutes
- Strong. Dual suppression via receptor antagonism
- Non-competitive synergy. Removes feedback brake while stimulating secretion
- CJC-1295 (DAC) + Ipamorelin
- Modified GHRH-R + GHS-R1a
- 280–340%
- 5–8 days (blunted peaks)
- Strong initially, desensitises over time
- 2× weekly
- Prolonged half-life flattens physiologic pulses